Vistra: A Flicker in the Grid

These regulators, a committee of perfectly polished shoes and impeccably starched collars, have proposed measures to… curb power costs. Curb! As if one could simply curb the boundless ambition of progress! They wish, it seems, for these hyperscalers – these digital landowners – to generate their own power. A charming notion, if one overlooks the inherent chaos of expecting anyone to actually do anything efficiently.

Stocks: A World of Difference

Until 2015, it wasn’t like this. Everything was roughly equal. Then the American tech stocks, the so-called Magnificent Seven, started to climb. They climbed and climbed, pulling the whole market along for the ride. Now, U.S. stocks average a forward P/E of 28. The rest of the world? Closer to 19. It’s like one kid hoarding all the candy.

Hycroft: A Gold Rush…Maybe

They announced an “increased assessment” of their resources. “Assessment.” What does that even mean? They looked at the dirt and decided there was… more dirt? More potential dirt? It’s just marketing speak. And they expect us to get excited? Honestly, the phrasing is just… sloppy.

Morgan Stanley: A Perfectly Fine Bank

During the pandemic, when I was mostly just trying to remember which day it was, Morgan Stanley went on a bit of a shopping spree. Twenty billion dollars, they spent on E*TRADE and Eaton Vance. It struck me as…bold. Like buying a yacht during a hurricane. But it worked. They’re now a top asset and wealth management firm. Which is good for them. I mostly manage my own assets, which mostly consist of a slightly chipped ceramic frog and a growing pile of unopened mail.

A Seed in Barren Ground

Vertex has reaped a good harvest from Alyftrek, Trikafta, and the like – solid work, to be sure. They predict further bounty from Casgevy, a gene-editing therapy for sickle cell and thalassemia. But the true promise lies not just in easing suffering, but in curing it. And that, friend, is where CRISPR Therapeutics holds the seed.

Nebius & UiPath: A Matter of Speculation

Nebius, a company dedicated to the construction of AI infrastructure—powered, naturally, by Nvidia’s hardware—is scaling with a velocity that would impress even the most ardent devotee of progress. The recent financial reports—a 547% surge in quarterly revenue, 479% year-on-year—are, admittedly, impressive. But one is reminded of a particularly flamboyant tulip bulb; a spectacular bloom, certainly, but lacking the substance to endure. The company remains, as yet, unburdened by the inconvenience of profit, and its capital expenditure is, to put it mildly, substantial.

Bybit EU: Stablecoins, Savings, and Sarcasm – Larry David Style

So, Bybit EU decided to launch these reward programs for USDC and EURC-you know, the stablecoins that are as exciting as a Tuesday night in. Circle issued them, and now Bybit’s all like, “Let’s make Europe great again, one regulated stablecoin at a time.” Because nothing says “financial revolution” like complying with MiCA rules. Savings and steady participation? Sure, because who doesn’t love a good nap in the financial markets?

Mesirow’s Gamble: Akre Focus ETF

They picked up 2,012,662 shares. A decent chunk. The valuation, as of December 31st, 2025, matched the average trading price. Which, honestly, is just good housekeeping. It’s the messy bits that worry me. Like, what were they thinking? Or, more accurately, what were they trying to signal?

A Quiet Disposition: Observing Symbotic’s Insider Trade

One wonders, naturally, about the scale of this parting. It appears to be the most substantial single divestiture made by Ms. Freve to date, exceeding both the median and the mean of her previous transactions. A curious detail, though perhaps unremarkable in the grand scheme. The reduction in her direct holdings, from eight thousand, eight hundred and forty-five shares to a mere five hundred and thirty-nine, is more significant. A shrinking estate, one might say, though hardly a ruinous one. It leaves her with a stake representing a fraction – a mere 0.0005 percent – of the company’s total outstanding shares. A modest holding, barely sufficient to command a view from the gallery.